ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
128.508,67
1,09%
S&P 500
5.127,79
1,26%
US Dollar vs BRL
5,09658
0,47%
Bitcoin
63.088,19
0,31%
Brent Oil
82,765
0,00%
Registration Strip Icon for tools Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Alterity Therapeutics Limited (ATHE)

  7. Alterity Therapeutics Limited (ATHE) Notícias

ATHE

Alterity Therapeutics (ATHE)

Alterity Therapeutics Limited
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:ATHE
DataHoraFonteTítuloCódigoCompanhia
30/04/202408:25GlobeNewswire Inc.Appendix 4C – Q3 FY24 Quarterly Cash Flow ReportNASDAQ:ATHEAlterity Therapeutics Limited
29/04/202408:25GlobeNewswire Inc.Alterity Therapeutics Presents New Data Demonstrating Potential of ATH434 to Treat Rare Neurodegenerative Disease Friedreich’s AtaxiaNASDAQ:ATHEAlterity Therapeutics Limited
17/04/202408:25GlobeNewswire Inc.Alterity Therapeutics Parkinson’s Disease and Multiple System Atrophy Data Featured at the American Academy of Neurology (AAN) 2024 Annual MeetingNASDAQ:ATHEAlterity Therapeutics Limited
10/04/202408:25GlobeNewswire Inc.Alterity Therapeutics to Present New Data on ATH434 at the World Orphan Drug Congress USA 2024NASDAQ:ATHEAlterity Therapeutics Limited
26/03/202411:25GlobeNewswire Inc.Alterity Therapeutics Receives a A$3.9 Million Research & Development Tax Incentive RefundNASDAQ:ATHEAlterity Therapeutics Limited
20/02/202412:25GlobeNewswire Inc.Alterity Therapeutics to Present New Data at the Upcoming American Academy of Neurology 2024 Annual MeetingNASDAQ:ATHEAlterity Therapeutics Limited
15/02/202419:29Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ATHEAlterity Therapeutics Limited
15/02/202419:28Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ATHEAlterity Therapeutics Limited
06/02/202409:25GlobeNewswire Inc.Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Second ReviewNASDAQ:ATHEAlterity Therapeutics Limited
29/01/202409:24GlobeNewswire Inc.Alterity Therapeutics to Participate in the ShareCafe Hidden Gems Webinar This WeekNASDAQ:ATHEAlterity Therapeutics Limited
22/01/202409:25GlobeNewswire Inc.Alterity Therapeutics Issues Shareholder Letter Highlighting Pipeline Advances and Key Upcoming MilestonesNASDAQ:ATHEAlterity Therapeutics Limited
21/12/202302:30GlobeNewswire Inc.Alterity Therapeutics Appoints Phillip Hains as Chief Financial OfficerNASDAQ:ATHEAlterity Therapeutics Limited
04/12/202318:35GlobeNewswire Inc.Alterity Therapeutics to Host Webcast to Discuss ATH434 Efficacy Data in Primates and Recent Clinical ProgressNASDAQ:ATHEAlterity Therapeutics Limited
04/12/202309:25GlobeNewswire Inc.Alterity Therapeutics Reports Positive Efficacy Data for ATH434 in a Primate Model of Parkinson’s DiseaseNASDAQ:ATHEAlterity Therapeutics Limited
27/11/202309:25GlobeNewswire Inc.Alterity Therapeutics Announces Presentation of Novel Biomarker Data for Evaluation of Multiple System AtrophyNASDAQ:ATHEAlterity Therapeutics Limited
16/11/202309:25GlobeNewswire Inc.Alterity Therapeutics Announces Presentation of New Data Demonstrating Novel Mechanisms of ATH434NASDAQ:ATHEAlterity Therapeutics Limited
08/11/202309:25GlobeNewswire Inc.Alterity Therapeutics Completes Enrolment in ATH434-201 Phase 2 Clinical Trial in Multiple System AtrophyNASDAQ:ATHEAlterity Therapeutics Limited
30/10/202308:25GlobeNewswire Inc.Appendix 4C – Q1 FY24 Quarterly Cash Flow ReportNASDAQ:ATHEAlterity Therapeutics Limited
26/10/202301:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ATHEAlterity Therapeutics Limited
31/08/202308:25GlobeNewswire Inc.Alterity Therapeutics Presents New Data on Multiple System Atrophy, a Rare Parkinsonian DisorderNASDAQ:ATHEAlterity Therapeutics Limited
23/08/202308:25GlobeNewswire Inc.Alterity Therapeutics Granted New Composition of Matter Patent in Europe for Neurodegenerative Diseases including Parkinson’s and Alzheimer’sNASDAQ:ATHEAlterity Therapeutics Limited
22/08/202308:25GlobeNewswire Inc.Alterity Therapeutics Rare Disease Natural History Study to be Featured at the International Congress of Parkinson’s Disease and Movement DisordersNASDAQ:ATHEAlterity Therapeutics Limited
15/08/202308:25GlobeNewswire Inc.Alterity Therapeutics Receives a $4.74 million Research & Development Tax Incentive RefundNASDAQ:ATHEAlterity Therapeutics Limited
31/07/202308:52GlobeNewswire Inc.Appendix 4C – Q4 FY23 Quarterly Cash Flow ReportNASDAQ:ATHEAlterity Therapeutics Limited
26/07/202308:25GlobeNewswire Inc.Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as PlannedNASDAQ:ATHEAlterity Therapeutics Limited
21/06/202308:25GlobeNewswire Inc.Alterity Therapeutics to Present in MST Access Rare Diseases, Rich Returns Forum on 22 June 2023NASDAQ:ATHEAlterity Therapeutics Limited
21/06/202307:09Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:ATHEAlterity Therapeutics Limited
30/05/202308:25GlobeNewswire Inc.Alterity Therapeutics Initiates Second Phase 2 Study in Rare Parkinsonian DisorderNASDAQ:ATHEAlterity Therapeutics Limited
19/05/202308:25GlobeNewswire Inc.Alterity Therapeutics CEO David Stamler to Present at the SHARE Series Monday Management Update on Monday, May 22, 2023NASDAQ:ATHEAlterity Therapeutics Limited
10/05/202308:25GlobeNewswire Inc.Appendix 4C – Q3 FY23 Quarterly Cash Flow ReportNASDAQ:ATHEAlterity Therapeutics Limited
 Apresentando as notícias mais relevantes sobre:NASDAQ:ATHE

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
HOOT4
HOTEIS OTHON PN
BOV
PRIO3
PETRORIO ON
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados